-
Valentyn Oksenych, PhD
lab.oksenych@gmail.com
Academic interests
DNA in our cells is constantly damaged by various internal and external factors. To maintain genomic stability, the cells develop multiple DNA repair pathways. Mutations in DNA repair genes lead to disorders in humans. Non-Homologous End-Joining (NHEJ) fixes the DNA double-strand breaks (DSB) throughout the cell cycle. NHEJ is required for the development of immune and nervous systems and to suppress medulloblastoma.
NHEJ consists of Ku70, Ku80, XLF, XRCC4, DNA Ligase 4, DNA-PKcs, Artemis, XLS/PAXX, APLF, Mri/Cyren. There is a complex genetic interaction between the NHEJ factors (eg, Oksenych et al., PNAS, 2013; Xing et al., DNA repair, 2017; Castaneda-Zegarra et al., DNA repair, 2019; Xing and Oksenych, FEBS open bio, 2019; Castaneda-Zegarra et al., Aging, 2020; Castaneda-Zegarra et al., Scandinavian Journal of Immunology, 2020).
In response to DNA damage, there is a complex process that includes the activation of multiple enzymes and modifications of proteins, such as histones surrounding the DSBs. This process is called the DNA damage response (DDR) pathway. It is facilitated by protein kinases ATM and DNA-PKcs, scaffold proteins MDC1 and 53BP1, ubiquitin-ligases RNF8 and RNF168, and many other proteins. During the DDR, histones are phosphorylated, ubiquitylated, methylated, acetylated, SUMOylated, NEDDylated, etc (Zha et al., Nature, 2011; Oksencyh et al., PNAS, 2012; Kumar et al., DNA repair, 2014; Beck et al. al., Biomolecules, 2020). I am attempting to understand the complexity of DDR, as well as its role in the development of the immune system and in cancer suppression.
Both NHEJ and DDR pathways are involved in immune system development, including the V(D)J recombination in developing B and T lymphocytes, and the Class Switch Recombination (CSR) in mature B cells.
Translocations associated with V(D)J recombination and class switch recombination (CSR) can be detected using High Throughput Genome-Wide Translocation sequencing (HTGTS). I collaborate with researchers at Karolinska Institutet and Harvard Medical School to develop HTGTS-based assays using primary human B cells.
Several drug candidates were identified to be used in cancer and immune disease treatments. I collaborate with researchers at UiO and local hospitals to validate and select the best options for further translation to the clinic.
Background
2015-2022. Researcher, principal investigator. NTNU – Trondheim, Norway
2021-2022. Lecturer. University of Stavanger, Stavanger, Norway
2020-2020. Researcher. The Arctic University of Norway – Tromsø (UiT)
2018-2020. Visiting Researcher. Karolinska Institutet, Sweden
2014-2015. Postdoc. University of Copenhagen, Denmark
2010-2014. Postdoc. Harvard Medical School, USA
2005-2009. PhD candidate. IGBMC, University of Strasbourg, France
Past projects and awards (ca. 3 M€)
2020-2021. Karolinska Institutet (KI Foundations and Funds). #2020-02155
2020-2021. Health Authority of Central Norway. #38811
2019-2022. Award in innovation, enabling technologies, NTNU, Norway
2018-2019. NTNU PES and POS grants, Norway
2018-2019. Research Council of Norway, FRIPRO. #291217
2017-2021. Outstanding Academic Fellow Award, NTNU, Norway
2017-2020. Norwegian Cancer Society, Open call. #182355
2016-2019. Research Council of Norway, FRIMEDBIO. #249774
2016-2018. Research Council of Norway, FRIPRO. #270491
2016-2018. Health Authority of Central Norway. #13477
2015-2017. Lundbeck Fellowship, University of Copenhagen, Denmark
2008-2009. Anti-Cancer Research Association (ARC), France
2007-2008. Anti-Cancer Research Association (ARC), France
2005 Mobility grant, IBB – Academy of Science, Warsaw, Poland
Keywords: B cells, DNA repair, mouse models, Genetics, Immunology
Alumni (Oksenych group, NTNU)
Graduated PhD students:
2. Sergio Miguel Castaneda-Zegarra (2019-2022)
Graduated MSc students:
8. Sergio Miguel Castaneda-Zegarra (2018-2019; enrolled in Bergen-UiB and Trondheim-NTNU)
9. Amin Alirezaylavasani (2018-2020)
11. Kalaiyarasi Ragunathan (2018-2020)
Visiting students:
12. Kimiko Teyama (てやまんぬ, MD student, Japan; 2017)
13. Julia Werner (Erasmus student, Heidelberg University, Germany; 2019)
14. Max Tkachov (MSc student, NTNU, Norway; 2019-2020)
Postdocs:
15. Raquel Gago-Fuentes (2016-2018)
Research assistants:
17. Stefano Bradamante (2016-2017)
Commissions of trust
Reviewer (63 journals; 217 reviews).
Aging (4); AITE (1); Antioxidants (8); Biology (2); Biomed Research International (2); Biomedical Journal (1); Biomedicine & Pharmacotherapy (3); Biomedicines (5); Biomolecules (6); Bioorganic Chemistry (1); BMJ Public Health (1); Cancers (28); Cell cycle (5); Cells (6); Cellular and Molecular Life Sciences (3); Computational and Structural Biotechnology J (1); Coronaviruses (3); Current Oncology (1); Cytometry Part A (2); Endocrine Regulations (1); Experimental and Therapeutic Medicine (1); FEBS journal (6); FEBS Open Bio (10); Frontiers in Bioengineering and Biotechnology (1); Frontiers in Bioscience-Landmark (1); Frontiers in Cell and Developmental Biology (4); Frontiers in Genetics (1); Frontiers in Immunology (8); Frontiers in Medicine (1); Frontiers in Microbiology (2); Frontiers in Molecular Biosciences (3); Frontiers in Oncology (3); Frontiers in Pharmacology (1); Gene expression (1); Genomics (6); IJMM (2); IJMS (34); International Journal of Oncology (1); Journal of Cellular Physiology (1); Journal of Immunological Methods (1); Journal of Personalized Medicine (1); JoVE (1); Medicine (1); Metabolites (1); Microorganisms (3); Mini-Reviews in Medicinal Chemistry (1); Molecular Medicine Reports (1); Molecules (2); NAR (3); NeuroSci (1); Oncology Letters (5); Oncology Reports (2); Oxidative Medicine and Cellular Longevity (2); Phytomedicine (4); PLOS One (2); Process Biochemistry (1); Recent Patents on Biotechnology (2); Reproduction (2); Scientific Reports (3); Toxicology in vitro (1); Vaccines (2); Viruses (1); World Academy of Sciences Journal (1).
WoS profile: https://www.webofscience.com/wos/author/record/1501536
Editor (10 journals; 3EB, editorial board; 7 AE, academic editor).
- Biomolecules (2019-now; EB, AE, guest editor).
- Frontiers in Bioscience (2021-2022; EB).
- Frontiers in Bioengineering-and-Biotechnology (2020-now; AE).
- Frontiers in Endocrinology (2023-now; AE).
- Frontiers in Immunology (2021-now; AE, guest editor).
- Frontiers in Microbiology (2018-now; AE).
- Frontiers in Oncology (2021-2023; AE, guest editor).
- Frontiers in Pediatrics (2021; AE).
- Microbes&Immunity (2023-now; EB).
- Viruses (2021-2023; AE, guest editor).
Advisory Board
Preprints.org (2023-now)
Grant evaluation (99, in 6 countries, for 7 agencies).
MSc graduation committee (2, in Norway).
- NTNU, Norway. Internal sensor: Aliaksandr Maisiuk (2020);
- NTNU, Norway. Internal sensor: Klara Krpina (2020).
PhD graduation committee (4, in 3 countries).
- NTNU, Norway: Karine Bjørås (2017; administrator, third opponent)
- NTNU, Norway: Katarzyna Anna Baranowska (2018; dispute leader)
- Institute Pasteur, France: Wenming Wei (2020; external sensor)
- Pondicherry University, India: Muthaiyan Mathavan (2021; external sensor)
INVITED LECTURES (27)
- 2024. University of Oslo, Ahus, Lorenskog Campus, Norway (March)
- 2023: University of Bergen-Broegelmann Research Laboratory (September 6)
- 2023: University of Oslo, NCMM (June, online)
- 2023: Arctic University of Norway, UiT – Tromsø, Norway (february, online)
- 2022: NMBU, Ås, Norway
- 2022: Arctic University of Norway, UiT – Tromsø, Norway (June, online)
- 2022: University of Stavanger, Norway (June)
- 2022: University of Oslo, Norway (June)
- 2022: University of Tartu, Estonia (April, online)
- 2022: University of Stavanger, Norway (March, online)
- 2021: University of Oslo, Norway (February)
- 2021: University of Oslo, Norway
- 2020: University of Oslo, Norway (online)
- 2020: UiT The Arctic University of Norway, Tromsø, Norway
- 2019: University of Aarhus, Denmark
- 2019: Pasteur Institute, Paris, France
- 2019: University of Innsbruck, Austria
- 2019: University of Helsinki, Finland
- 2018: University of Tartu, Estonia
- 2018: Karolinska Institutet, Sweden
- 2018: University of Oslo, Norway
- 2016: European Commission, interview for ERC grant, Brussels, Belgium
- 2016: University of Helsinki, Biomedicum Helsinki Seminar, Finland
- 2009: University of Stanford (2 times, September)
- 2009: Harvard Medical School (October)
- 2009: Harvard Medical School (September)
CONFERENCE TALKS (13)
- 2021: Biotechnology seminar NTNU, Trondheim, Norway
- 2019: Scandinavian Society for Immunology-SSI meeting, Geilo, Norway
- 2019: First Immunology and Infection meeting, Berlin, Germany
- 2017: Molecular mechanisms underlying carcinogenesis and neurodegeneration, Trondheim, Norway
- 2017: DNA and RNA dynamics workshop (organizer, chairman, speaker), Trondheim, Norway
- 2017: Norwegian Biochemical Society meeting, Oppdal, Norway
- 2017: Norwegian Biochemical Society Annual meeting, Storfjell, Norway
- 2016: DNA repair, Epigenetics, and Translational Medicine, Trondheim, Norway
- 2016: Norwegian Biochemical Society meeting, Åre, Sweden
- 2016: Norwegian Biochemical Society Annual Meeting, Tromsø, Norway
- 2015: Tomas Lindahl conference on DNA Repair, Oslo, Norway
- 2008: DNA repair meeting, Porto, Portugal
- 2007: DNA repair meeting, Sicily, Italy
Social media and research profiles
Twitter: https://twitter.com/oksenych
LinkedIn: https://www.linkedin.com/in/oksenych/
Facebook: https://www.facebook.com/DNArepairNHEJ
Youtube: https://www.youtube.com/channel/UCXy_OvlRYdZ1AwjIrIDw8OA
Research gate: https://www.researchgate.net/profile/Valentyn-Oksenych
Scopus: https://www.scopus.com/authid/detail.uri?authorId=16242096600
ORCID: https://orcid.org/0000-0002-5088-3791
Sci Profiles: https://sciprofiles.com/profile/oksenych
Frontiers Loop: https://loop.frontiersin.org/people/695622/overview
Web of Science: https://www.webofscience.com/wos/author/record/1501536
wikipedia: https://no.wikipedia.org/wiki/Valentyn_Oksenych
Publications and metrics
67 published papers (2007-2024), including 12 as a first (or co-first) and 30 as a corresponding author. The h-index: 26, i10-index: 41; the total number of citations: is 2783 (Google Scholar, March 2024).
I have published in Nature (1), Molecular Cell (2), NAR (1), EMBOj (1), PNAS (3), CMLS (1), PLOS Genetics (1), Aging (1); DNA repair (4), Cell Cycle (1), etc.
Pubmed: https://pubmed.ncbi.nlm.nih.gov/?term=oksenych
Google Scholar: https://scholar.google.com/citations?user=u9FJXScAAAAJ
67*. Petakh P, Behzadi P, Oksenych V*, Kamyshnyi O. (2024) Current Treatment Options for Leptospirosis: A Mini-Review. Frontiers in Microbiology (accepted, April 2024)
66*. Belenichev I, Popazova O, Bukhtiyarova N, Savchenko D, Oksenych V*, Kamyshnyi O. (2024) Nitric oxide in the mechanisms of cell death and cytoprotection. Antioxidants (accepted, April 2024)
65*. Kamenshchyk A, Belenichev I, Oksenych V*, Kamyshnyi A. (2024) Combined pharmacological modulation of translational and transcriptional activity signaling pathways as a promising therapeutic approach in children with myocardial changes. Biomolecules. 2024, 14(4), 477; https://doi.org/10.3390/biom14040477
64*. Petakh P, Oksenych V*, Kamyshnyi O. (2024) Exploring Leptospira interrogans FDAARGOS_203: Insights into AMR and Anti-phage Defense. Microorganisms 2024, 12(3), 546; https://doi.org/10.3390/microorganisms12030546
63. Ianevski A, Frøysa IT, Lysvand H, Calitz C, Smura T, Nilsen HJS, Høyer E, Afset JE, Sridhar A, Wolthers KC, Zusinaite E, Tenson T, Kurg R, Oksenych V, Galabov AS, Stoyanova A, Bjørås M, Kainov DE. (2024) The combination of pleconaril, rupintrivir, and remdesivir efficiently inhibits enterovirus infections in vitro, delaying the development of drug-resistant virus variants. Antiviral Research. 2024 Apr; 224:105842. doi: 10.1016/j.antiviral.2024.105842
62*. Petakh P, Kamyshna I, Oksenych V*, Kamyshnyi O. (2024) Metformin Alters mRNA Expression of FOXP3, RORC, and TBX21 and Modulates Gut Microbiota in COVID-19 Patients with Type 2 Diabetes. Viruses 2024, 16(2), 281; https://doi.org/10.3390/v16020281
61. Petakh P, Oksenych V, Kamyshna I, Boisak I, Lyubomirskaya K, Kamyshnyi O. (2024) Exploring the Complex Interplay: Gut Microbiome, Stress, and Leptospirosis. Front. Microbiol. doi: 10.3389/fmicb.2024.1345684
60. Petakh P, Oksenych V, Kamyshna I, Boisak I, Lyubomirskaya K, Kamyshnyi O. (2024) Exploring the Interplay Between Posttraumatic Stress Disorder, Gut Microbiota, and Inflammatory Biomarkers: A Comprehensive Meta-Analysis. Front. Immunol. doi: 10.3389/fimmu.2024.1349883
59*. Buchynskyi M, Oksenych V*, Kamyshna I, Kamyshnyi O. (2024) Exploring Paxlovid Efficacy in COVID-19 Patients with MAFLD: Insights from a Single-Center Prospective Cohort Study. Viruses 2024 Jan 12;16(1):112. doi: 10.3390/v16010112.
58*. Popazova O, Belenichev I, Yadlovskyi O, Oksenych V*, Kamyshnyi A. (2023) Altered Blood Molecular Markers of Cardiovascular Function in Rats After Intrauterine Hypoxia and Drug Therapy. CIMB 2023, 45(11), 8704-8715; https://doi.org/10.3390/cimb45110547
57*. Popazova O, Belenichev I, Bukhtiyarova N,Ryzhenko V, Oksenych V*, Kamyshnyi A (2023). Cardioprotective Activity of Pharmacological Agents Affecting NO Production and Bioavailability in the Early Postnatal Period after Intrauterine Hypoxia in Rats. Biomedicines 2023, 11(10), 2854; https://doi.org/10.3390/biomedicines11102854
56. Ravlo Е, Ianevski А, Starheim Е, Wang W, Ji P, Lysvand H, Smura T, Kivi G, Voolaid ML, Plaan K, Ustav M, Ustav M Jr., Zusinaite E, Tenson T, Kurg R, Oksenych V, Walstad K, Nordbø SA, Kaarbø M, Ernits K, Bjørås M, Kainov DE, Fenstad MH. (2023). Boosted production of antibodies which neutralized different SARS-CoV-2 variants in a COVID-19 convalescent following mRNA vaccination – a case study. Int J Infect Dis. 2023 Oct 16:S1201-9712(23)00748-8. doi: 10.1016/j.ijid.2023.10.011
55*. Kamenshchyk A, Gonchar M, Oksenych V*, Kamyshnyi A. (2023). Association of myocardial changes and gene expression of the NFATC1 and NFATC4 – calcineurin signaling pathway in children with bicuspid aortic valve. Children 2023 10(9), 1434; https://doi.org/10.3390/children10091434
54*. Buchynskyi M, Oksenych V*, Kamyshna I, Vari SG, Kamyshnyi A (2023). Genetic Predictors of Comorbid Course of COVID-19 and MAFLD: A Comprehensive Analysis. Viruses 2023, 15(8), 1724; https://doi.org/10.3390/v15081724
53. Petakh P, Kamyshna I, Oksenych V, Kainov D, Kamshnyi A (2023). Metformin Therapy Changes Gut Microbiota Alpha-Diversity in COVID-19
Patients with Type 2 Diabetes: The Role of SARS-CoV-2 Variants and Antibiotic
Treatment. Pharmaceuticals 2023, 16(6), 904; https://doi.org/10.3390/ph1606090452. Petakh P, Oksenych V, Kamyshnyi A (2023). The F/B Ratio as a Biomarker for Inflammation in COVID-19 and T2D: Impact of Metformin. Biomedicine & Pharmacotherapy 2023 Jul;163:114892. https://doi.org/10.1016/j.biopha.2023.114892
51. Buchynskyi M, Kamyshna I, Oksenych V, Zavidniuk N, and Kamyshnyi A. (2023) The intersection of COVID-19 and MAFLD: An overview of the current evidence. Viruses 2023, 15(5), 1072; https://doi.org/10.3390/v15051072
50. Kamyshnyi A, Koval H, Kobevko O, Buchynskyi M, Oksenych V, Kainov D, Lyubomirskaya K, Kamyshna I, Potters G, and Moshynets O. (2023) Therapeutic Effectiveness of Interferon-α2b Against COVID-19 with community-acquired pneumonia: The Ukrainian Experience. IJMS 2023, 24(8), 6887; https://doi.org/10.3390/ijms24086887
49*. Upfold NLE, Petakh P, Kamyshnyi A, and Oksenych V*. (2023) Tyrosine Kinase Inhibitors Target B Lymphocytes. Biomolecules 2023, 13(3), 438; https://doi.org/10.3390/biom13030438
48*. Oksenych V*. (2023) Plasticity of Immune Cells in Tumor Microenvironment. Front Oncol. https://doi.org/10.3389/fonc.2023.1160961
47*. Buchynskyi M, Kamyshna I, Lyubomirskaya K, Moshynets E, Kobyliak N, Oksenych V*, Kamyshnyi A. (2023) Efficacy Of Interferon Alpha For The Treatment Of Hospitalized Patients With COVID-19: A Meta-Analysis. Front Immunol. https://doi.org/10.3389/fimmu.2023.1069894
46*. Oksenych V*. (2022) DNA repair and immune response: Editorial. Biomolecules 2023, 13(1), 84; https://doi.org/10.3390/biom13010084
45*. Petakh P. Isevych V. Kamyshnyi A. Oksenych V*. (2022) Weil’s Disease—Immunopathogenesis, Multiple Organ Failure, and Potential Role of Gut Microbiota. Biomolecules. 2022, 12(12), 1830; https://doi.org/10.3390/biom12121830
44. Ianevski A, Ahmad S, Anunnitipat K, Oksenych V, Zusinaite E, Tenson T, Bjørås M, Kainov D. (2022) Seven classes of antiviral agents. CMLS. 2022, 79:605 https://doi.org/10.1007/s00018-022-04635-1
43*. Haghmorad D, Yousefi B, Eslami M, Rashidy-Pour A, Tarahomi M, Tavaf MJ, Soltanmohammadi A, Zargarani S, Kamyshnyi A, Oksenych V*. (2022) Oral administration of Myelin Oligodendrocyte Glycoprotein attenuates experimental autoimmune encephalomyelitis through induction of Th2/Treg cells and suppression of Th1/Th17 immune responses. CIMB. 2022, 44(11), 5728-5740; https://doi.org/10.3390/cimb44110388
42*. Kainov D, Oksenych V.* (2022) Broad-Spectrum Antivirals and Antiviral Combinations: An Editorial Update. Viruses. 2022, 14(10), 2252; https://doi.org/10.3390/v14102252
41. Ianevski A, Zusinaite E, Tenson T, Oksenych V, Wang W, Afset JE, Bjørås M, Kainov DE. (2022) Novel synergistic anti-enteroviral drug combinations. Viruses. 2022, 14(9), 1866; https://doi.org/10.3390/v14091866
40. Ianevski A, Simonsen RM, Myhre V, Tenson T, Oksenych V, Bjørås M, Kainov DE. (2022) DrugVirus.info 2.0: an integrative data portal for broad-spectrum antivirals (BSA) and BSA-containing drug combinations (BCCs). Nucleic Acids Research. 2022 May 24:gkac348. https://doi.org/10.1093/nar/gkac348
39. Ianevski A, Yao R, Simonsen RM, Myhre V, Ravlo E, Kaynova GD, Zusinaite E, White JM, Polyak SJ, Oksenych V, Windisch MP, Pan Q, Lastauskienė E, Vitkauskienė A, Matukevičius A, Tenson T, Bjørås M, Kainov DE. (2022) Mono- and combinational drug therapies for global viral pandemic preparedness. iScience https://doi.org/10.1016/j.isci.2022.104112
38*. Petakh P, Kamyshna I, Nykyforuk A, Oksenych V*, Korda M, Kamyshnyi A. (2022) Immunoregulatory intestinal microbiota and COVID-19 in patients with type two diabetes: a double-edged sword. Viruses. Feb 25;14(3):477. https://doi.org/10.3390/v14030477
37. Oksenych V, Kainov DE. (2022). Editorial: Broad-spectrum Antivirals and Antiviral Drug Combinations. Viruses. 2022 Feb 1;14(2):301. https://doi.org/doi:10.3390/v14020301
36*. Oksenych V*, Dan Su, Daniel JA. (2021). Acetyltransferases GCN5 and PCAF Are Required for B Lymphocyte Maturation in Mice. Biomolecules. 12(1), 61 https://doi.org/10.3390/biom12010061.
Editor’s Choice Article 2022. Read it here: https://doi.org/10.3390/biom12010061.
35*. Oksenych V*, and Kainov D. (2021) Editorial: DNA Damage Response. Editorial. Biomolecules Jan 19;11(1),123; https://doi.org/10.3390/biom11010123
34. Ianevski A, Yao R, Zusinaite E, Lello LS, Wang S, Jo E, Yang J, Lysvand H, Løseth K, Oksenych V, Tenson T, Windisch MP, Poranen M, Nieminen AI, Nordbø SA, Fenstad MH, Grødeland G, Aukrust P, Trøseid M, Kantele A, Lastauskiene E, Vitkauskiene A, Legrand N, Merits A, Bjørås M, Kainov D. (2021) Synergistic interferon alpha-based antiviral combinations. Viruses https://doi.org/10.1101/2021.01.05.425331
33. Ianevski A, Yao R, Lysvand H, Grødeland G, Legrand N, Oksenych V, Zusinaite E, Tenson T, Bjørås M, Kainov DE. (2021) Nafamostat-interferon-alpha combination suppresses SARS-CoV-2 infection by targeting cooperatively host TMPRSS2 in vitro and in vivo. Viruses 13(9), 1768 https://doi.org/10.1101/2021.06.16.448653
32. Ianevski A, Yao R, Zusinaite E, Lysvand H, Oksenych V, Tenson T, Bjørås M, Kainov D. (2021) Active components of commonly prescribed medicines affect influenza A virus-host cell interaction: a pilot study. Viruses 13(8), 1537; https://doi.org/10.3390/v13081537
31*. Gago-Fuentes R., and Oksenych V.* (2020) Non-Homologous end Joining Factors XLF, PAXX and DNA-PKcs are Required to Maintain the Neural Stem and Progenitor Cell Population. Biomolecules 2021, 11(1), 20; https://doi.org/10.3390/biom11010020
30*. Castañeda-Zegarra S, Zhang S, Alirezaylavasani A, Fernandez-Berrocal M, Yao R, and Oksenych V.* (2020) Severe immunodeficiency in mice lacking DNA repair factors XLF and Mri. Aging https://doi.org/10.18632/aging.202346
29*. Ragunathan K, Upfold NLE, and Oksenych V*. (2020) Interaction between Fibroblasts and Immune Cells Following DNA Damage Induced by Ionizing Radiation. IJMS 21(22), 8635; https://doi.org/10.3390/ijms21228635
28. Ianevski A, Yao R, Biza S, Zusinaite E, Männik A, Kivi G, Planken A, Kurg K, Tombak EM, Ustav M., Shtaida N, Kulesskiy E, Jo E, Yang J, Lysvand H, Løseth K, Oksenych V, Aas PA, Tenson T, Vitkauskiene A, Windisch MP, Fenstad MH, Nordbø SA, Ustav M, Bjørås M, Kainov D. (2020) Identification and tracking of antiviral drug combinations. Viruses. 12(10), 1178; https://doi.org/10.3390/v12101178
27*. Castañeda-Zegarra S, Fernandez-Berrocal M, Tkachev M, Yao R, Upfold NLE, and Oksenych V.* (2020) Genetic interaction between the non-homologous end joining factors during B and T lymphocyte development: in vivo mouse models. Scand J Immunol. e12936. https://doi.org/10.1111/sji.12936
26*. Beck C, Castañeda-Zegarra S, Huse C, Xing M, and Oksenych V.* (2020) Mediator of DNA Damage Checkpoint Protein 1 Facilitates V(D)J Recombination in Cells Lacking DNA Repair Factor XLF. Biomolecules 10(1), 60; https://doi.org/10.3390/biom10010060
25. Ianevski A, Kulesskiy E, Krpina K, Lou G, Aman Y, Bugai A, Aasumets K, Akimov Y, Bulanova D, Gildemann K, Arutyunyan AF, Susova OY, Zhuze AL, Ji P, Wang W, Holien T, Bugge M, Zusinaite E, Oksenych V, Lysvand H, Gerhold JM, Bjørås M, Johansen P, Waage A, Heckman CA, Fang EF, and Kainov DE (2020). Chemical, Physical and Biological Triggers of Evolutionary Conserved Bcl-xL-Mediated Apoptosis. Cancers 2020, 12(6), 1694; https://doi.org/10.3390/cancers12061694
24. Ianevski A, Yao R, Fenstad MH, Biza S, Zusinaite E, Reisberg T, Lysvand H, Løseth K, Landsem VM, Malmring JF, Oksenych V, Erlandsen SE, Aas PA, Hagen L, Pettersen CH, Tenson T, Afset JE, Nordbø SA, Bjørås M, and Kainov DE (2020) Potential Antiviral Options against SARS-CoV-2 Infection. Viruses 2020, 12(6), 642; https://doi.org/10.3390/v12060642
23. Andersen PI, Ianevski A, Lysvand H, Vitkauskiene A, Oksenych V, Bjørås M, Telling K, Lutsar I, Dampis U, Irie Y, Tenson T, Kantele A, and Kainov D. E. (2020) Discovery and Development of Safe-In-Man Broad-Spectrum Antiviral Agents. Int J Infect Dis. 2020 Feb 17. PMID: 32081774 https://doi.org/10.1016/j.ijid.2020.02.018
22*. Castañeda-Zegarra S, Huse C, Røsand Ø, Sarno A, Xing M, Gago-Fuentes R, Zhang Q, Alirezaylavasani A, Werner J, Ji P, Liabakk N, Wang W, Bjørås M, Oksenych V.* (2019) Generation of a Mouse Model Lacking the Non-Homologous End-Joining Factor Mri/Cyren. Biomolecules 9(12), 798
21*. Xing M, and Oksenych V.* (2019). Genetic interaction between DNA repair factors PAXX, XLF, XRCC4 and protein kinase DNA-PKcs in human cells. FEBS Open Bio. https://doi.org/10.1002/2211-5463.12681
20*. Castañeda-Zegarra S, Xing M, Gago-Fuentes R, Sæterstad S, Oksenych V.* (2019) Synthetic lethality between DNA repair factors Xlf and Paxx is rescued by inactivation of Trp53. DNA Repair (Amst). 73:164-169. https://doi.org/10.1016/j.dnarep.2018.12.002
19. Bohl K, Ianevski A, Than TT, Andersen PI, Kuivanen S, Teppor M, Zusinaite E, Dumpis U, Vitkauskiene A, Cox RJ, Kallio-Kokko H, Bergqvist A, Tenson T, Oksenych V, Bjoras M, Anthonsen MW, Shum D, Kaarbo M, Vapalahti O, Windisch MP, Superti-Furga G, Snijder B, Kainov D, Kandasamy R. (2019). Critical Nodes of Virus-Host Interaction Revealed Through an Integrated Network Analysis. Front Immunol. 2019 Oct 4;10:2186. https://doi.org/10.3389/fimmu.2019.02186
18. Ianevski A, Zusinaite E, Shtaida N, Kallio-Kokko H, Valkonen M, Kantele A, Telling K, Lutsar I, Letjuka P, Metelitsa N, Oksenych V, Dumpis U, Vitkauskiene A, Stašaitis K, Öhrmalm C, Bondeson K, Bergqvist A, Cox RJ, Tenson T, Merits A, Kainov DE. (2019) Low Temperature and Low UV Indexes Correlated with Peaks of Influenza Virus Activity in Northern Europe during 2010⁻2018. Viruses. 11(3). pii: E207. https://doi.org/10.3390/v11030207
17*. Dewan A, Xing M, Lundbæk MB, Gago-Fuentes R, Beck C, Aas PA, Liabakk NB, Sæterstad S, Chau KTP, Kavli BM, Oksenych V.* (2018). Robust DNA repair in PAXX-deficient mammalian cells. FEBS Open Bio 8(3):442-448
16*. Gago-Fuentes R, Xing M, Sæterstad S, Sarno A, Dewan A, Beck C, Bradamante S, Bjørås M, Oksenych V.* (2018). Normal development of mice lacking PAXX, the paralogue of XRCC4 and XLF. FEBS Open Bio 8(3):426-434
15. Ianevski A, Zusinaite E, Kuivanen S, Strand M, Lysvand H, Teppor M, Kakkola L, Paavilainen H, Laajala M, Kallio-Kokko H, Valkonen M, Kantele A, Telling K, Lutsar I, Letjuka P, Metelitsa N, Oksenych V, Bjørås M, Nordbø SA, Dumpis U, Vitkauskiene A, Öhrmalm C, Bondeson K, Bergqvist A, Aittokallio T, Cox RJ, Evander M, Hukkanen V, Marjomaki V, Julkunen I, Vapalahti O, Tenson T, Merits A, Kainov D. (2018). Novel activities of safe-in-human broad-spectrum antiviral agents. Antiviral Research. 154:174-182. https://doi.org/10.1016/j.antiviral.2018.04.016
14*. Xing M, Bjørås M, Daniel JA, Alt FW, Oksenych V.* (2017) Synthetic lethality between murine DNA repair factors XLF and DNA-PKcs is rescued by inactivation of Ku70. DNA Repair (Amst.) 57: 133-138
13. Bulanova D, Ianevski A, Bugai A, Akimov Y, Kuivanen S, Paavilainen H, Kakkola L, Nandania J, Turunen L, Ohman T, Ala-Hongisto H, Pesonen HM, Kuisma MS, Honkimaa A, Walton EL, Oksenych V, Lorey MB, Guschin D, Shim J, Kim J, Than TT, Chang SY, Hukkanen V, Kulesskiy E, Marjomaki VS, Julkunen I, Nyman TA, Matikainen S, Saarela JS, Sane F, Hober D, Gabriel G, De Brabander JK, Martikainen M, Windisch MP, Min JY, Bruzzone R, Aittokallio T, Vähä-Koskela M, Vapalahti O, Pulk A, Velagapudi V, Kainov DE. (2017). Antiviral Properties of Chemical Inhibitors of Cellular Anti-Apoptotic Bcl-2 Proteins. Viruses. 9(10). pii: E271. https://doi.org/10.3390/v9100271
12*(11*). Kumar V, Alt FW, Oksenych V.* (2014) Functional overlaps between XLF and the ATM-dependent DNA double strand break response. DNA Repair (Amst.) 16:11-22 Re-published by the same journal (reprint)
10. Oksenych V, Zhovmer A, Ziani S, Mari PO, Eberova J, Nardo T, Stefanini M, Giglia-Mari G, Egly JM, Coin F. (2013) Histone methyltransferase DOT1L drives recovery of gene expression after a genotoxic attack. PLoS Genet 9(7):e1003611
9. Oksenych V, Kumar V, Liu X, Guo C, Schwer B, Zha S, Alt FW. (2013) Functional redundancy between the XLF and DNA-PKcs DNA repair factors in V(D)J recombination and nonhomologous DNA end joining. PNAS 110(6):2234-9
8. Oksenych V, Alt FW, Kumar V, Schwer B, Wesemann DR, Hansen E, Patel H, Su A, Guo C. (2012) Functional redundancy between repair factor XLF and damage response mediator 53BP1 in V(D)J recombination and DNA repair. PNAS 109(7):2455-60
7#. Boboila C#, Oksenych V#, Gostissa M, Wang JH, Zha S, Zhang Y, Chai H, Lee CS, Jankovic M, Saez LMA, Nussenzweig MC, McKinnon PJ, Alt FW, Schwer B.* (2012) Robust chromosomal DNA repair via alternative end-joining in the absence of X-ray repair cross-complementing protein 1 (XRCC1). PNAS 109(7):2473-8 #co-first
6. Zha S, Guo C, Boboila C, Oksenych V, Cheng HL, Zhang Y, Wesemann DR, Yuen G, Patel H, Goff PH, Dubois RL, Alt FW. (2011) ATM Damage Response and XLF Repair Factor are Functionally Redundant In Joining DNA Breaks. Nature 469(7329):250-4
5. Oksenych V, Coin F. (2010) The long unwinding road: XPB and XPD helicases in damaged DNA opening. Cell Cycle 9 (1), 90-96
4.Zhovmer A, Oksenych V, Coin F. (2010) Two sides of the same coin: TFIIH complexes in transcription and DNA repair. The Scientific World JOURNAL 10, 633-643
3. Oksenych V, De Jesus BB, Zhovmer A, Egly JM, Coin F. (2009) Molecular insights into the recruitment of TFIIH to sites of DNA damage. EMBO J 28(19):2971-80
2. Coin F, Oksenych V, Mocquet V, Groh S, Blattner C, Egly JM. (2008) Nucleotide excision repair driven by the dissociation of CAK from TFIIH. Mol Cell 31(1):9-20
1. Coin F, Oksenych V, Egly JM. (2007) Distinct roles for the XPB/p52 and XPD/p44 subcomplexes of TFIIH in damaged DNA opening during nucleotide excision repair. Mol Cell 26(2):245-56
-
Subscribe
Subscribed
Already have a WordPress.com account? Log in now.
Valentyn Oksenych, PhD 